During the past decade, ProSciento, Inc. conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 7 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 6 clinical trials were completed. i.e. 46.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ProSciento, Inc." #1 sponsor was "Xeris Pharmaceuticals" with 2 trials, followed by "Zealand Pharma" with 2 trials sponsored, "Amgen" with 1 trials sponsored, "Arecor Limited" with 1 trials sponsored and "Cyclerion Therapeutics" with 1 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ProSciento, Inc." #1 collaborator was "ProSciento, Inc." with 3 trials as a collaborator, "Integrated Medical Development" with 1 trials as a collaborator, "SGS S.A." with 1 trials as a collaborator and "WCCT Global" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "ProSciento, Inc." are "Diabetes Mellitus, Type 1" (5 trials), "Hypoglycemia" (3 trials), "Diabetes Mellitus" (2 trials), "Diabetes Mellitus, Type 2" (2 trials) and "NAFLD" (2 trials). Many other conditions were trialed in "ProSciento, Inc." in a lesser frequency.

Most popular intervention types in "ProSciento, Inc." are "Drug" (19 trials), "Device" (2 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Dasiglucagon" (2 trials), "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule" (1 trials), "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule" (1 trials) and "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule" (1 trials). Other intervention names were less common.

The vast majority of trials in "ProSciento, Inc." are 21 trials for "All" genders.

Currently, there are NaN active trials in "ProSciento, Inc.". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in ProSciento, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ProSciento, Inc., 9 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".